Haijian He
Analyst · CICC. Please go ahead
Thank you. This is Henry. Happy to take all those three questions on the financial related matters. The first question is regarding the EBITDA breakeven, yeah, we do acknowledge that the EBITDA on a sequential basis, we actually dropped a little bit marginally. We noted that there are a few things on the line. First of all, if you look at the total expenses on the dollar value, actually, our sales, marketing and R&D expenses actually was quite stable. So there's no major changes on that. However, the booking of certain G&A expenses due to, for example, the Hong Kong Dual Primary Listing projects that we actually need to pay certain fees, as you may understand, that actually also eating up the bills as well. And also given this year, we do have certain cost-cutting, for example, the optimization of human capitals of the company. We need to pay certain compensations for the people they may choose other credit tracks for things like that. We did a batch of that arrangement in Q3. So especially towards the end of Q3. So the savings on the salary has not been reflected on expenses in Q3, while we need to pay even more for the compensation for the people that they choose other credit tracks. So in and out, you see actually the fluctuation and even increasing on certain expenses items. But I think these are the right thing to do for the company and the benefits on the cost of savings and expenses will be gradually released in Q3, and I think for some time down from Q1 next year. So that's actually quite clear on online reasons. So we don't worry too much about that a little fluctuation, but the online -- or the normalized operational expenses in Q3 already kind of declined. So given that, as you probably know that, our priority at this moment is improving the gross margin. As we mentioned, the gross margin has been improving from almost only 1% last Q3 -- Q4 last year to about 6.3% this quarter. That's actually a meaningful improvement. And if you look at the growth profit on a dollar value, we almost doubled from Q2 to Q3 from about RMB50 million to about RMB120 million for this quarter. So we do believe the improvement on the gross margin will be a first level of the driver of improving EBITDA and even -- and breakeven of EBITDA timing. So given on that, we think sometime for next year, we do hope the EBITDA margin kind of improving at a little bit faster pace compared with the gross margin sometime point of next year. And on the other side, we do hope that after we complete all the necessary capital market transactions, our expenses ratio will further come down as well. So that's the first point. The second point regarding the CapEx plan. I think this year, we're running relatively well. It's towards the low end of the capital budget for 2022. While we print the same level of the revenue target, I think which is a good sign. For the next two to three years, I think we may keep relatively the same level at around about RMB1 billion each year. And you may remember, we discussed that we may need to hit a certain server replacement cycles, sometime around like '25, '26. But I think so far, we feel comfortable regarding about RMB1 billion on capital expenditures. But given we do have about RMB5 billion cash. And right now, we have multiple access to the capital, not only from the stock market, for example, the long-term financing and the cheap leasing arrangements, et cetera. So we do hope over 90% of the capital expenditures we may find other ways to fund those capital expenditures outlay rather than tapping to our own net cash balance. I think that's going to be a good point on the capital structure, and we don't need to burn too much cash on hand. And the third question regarding the service, I think you're right. We do notice that the major U.S. cloud company has revised the DNA policy from four years to five years, last year. And some of them are discussing the shifting to six years, which actually reflecting the nature of the technology as they evolve because most of the new servers starting from these two years, for example, some of the expensive ones, we actually -- the cost -- the price point is high, but they actually can use, for example, 2 times of the price point, but they can use like 3 times, 4 times of the life cycle. So I think it does make sense for the U.S. peers to extend that. But given we do adopt a very conservative financial policy, we do not have any plan at this moment to extend our DNA policy, even though we understand extending from four years to five or even six years, we will have a relatively good impact on the gross margin because we have a lower G&A expenses. But at this moment, we do not any plan to revise that policy. But we may reserve that if we see other Chinese players change the policy. It's going to be an uplift to our gross margin, and reduce the D&A expenses. Thank you.